NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
January 6, 2004 • Volume 1 / Number 1 E-Mail This Document  |  View PDF Version  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
NCI Budget Outlook 2004

Director's Update

Featured Clinical Trial

Funding Opportunities

Cancer Research Highlights
Tamoxifen and Uterine Cancer

Anastrozole and Breast Cancer

Imatinib and Neuroblastoma

Legislative Update
2004 Appropriations

National Cancer Act 2003

NCI Testimony in Congress

States with Laws Related to Smoking in Restaurants

Notes
HPV Monograph

Kaplan to Leave CTEP

New Laboratory of Genetics Chief

Travel Award Created in Radiation Expert's Name

Yuspa to Receive Dermatology Award

Bishop Recognized for Teaching

Featured Meetings

Bulletin Archive

Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
View/Print PDF  View/Print PDF
Funding Opportunities

In vivo Cancer Imaging Exploratory/ Developmental Grants

PA-04-045
Application Receipt Dates: Feb. 1, 2004; June 1, 2004; Oct. 1, 2004; Feb. 1, 2005; June 1, 2005; Oct. 1, 2005

This initiative provides investigators at all career levels with funding for the initial development and/or feasibility testing of high-impact concepts. Research topics will fall within the entire spectrum of in vivo cancer imaging research, from basic discovery to preclinical testing and validation to early feasibility testing of those novel agents and technologies in small clinical trials.

For more information see http://cri.nci.nih.gov/index.cfm.

Inquiries: Dr. Anne Menkens, am187k@nih.gov

Clinical Cancer Therapy and Prevention Research

PA-04-046
Application Receipt Dates: Feb. 1, 2004; June 1, 2004; Oct. 1, 2004; Feb. 1, 2005; June 1, 2005; Oct. 1, 2005

The NCI seeks R01 applications to conduct translational, clinical, therapeutic, and preventive studies/trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists for translation of new anticancer agents into innovative cancer intervention studies/trials.

For more information see http://cri.nci.nih.gov/index.cfm.

Inquiries: Dr. Roy Wu, wur@mail.nih.gov

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov